Shopping Cart
Remove All
Your shopping cart is currently empty
VX5 is a humanized IgG1κ monoclonal antibody inhibitor targeting BCA-1/CXCL13. It significantly inhibits human CXCL13-mediated CXCR5 internalization and blocks the CXCL13-dependent chemotaxis and migration of both human and mouse B cells (with EC50 values of 105 nM for human tonsil cells and 253 nM for pre-B-697-hCXCR5 cells). VX5 is applicable in the study of autoimmune diseases such as multiple sclerosis and arthritis, as well as cancers like gastric lymphoma and colon cancer.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry | Inquiry |
| Description | VX5 is a humanized IgG1κ monoclonal antibody inhibitor targeting BCA-1/CXCL13. It significantly inhibits human CXCL13-mediated CXCR5 internalization and blocks the CXCL13-dependent chemotaxis and migration of both human and mouse B cells (with EC50 values of 105 nM for human tonsil cells and 253 nM for pre-B-697-hCXCR5 cells). VX5 is applicable in the study of autoimmune diseases such as multiple sclerosis and arthritis, as well as cancers like gastric lymphoma and colon cancer. |
| Synonyms | VX5/5261 |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.